新生儿有创机械通气中脑氧饱和度指导治疗:SafeBoosC-IIIv 随机临床试验第一步方案
SafeBoosC-IIIv 为研究者发起的多国随机实用优效性 III 期试验,分两步实施,本文为第一步方案。第一步计划纳入 1,610 例胎龄≥28+0 周、生后<28 天、预计有创机械通气≥24 h 且 6 h 内可启动脑氧监测的新生儿,1:1 随机至脑氧饱和度指导治疗或常规治疗,主要结局为 90 天时无住院天数。
要点
- 脑氧指导组按 SafeBoosC 治疗指南干预,对照为常规治疗。
- 主要结局为随机后 90 天无住院天数。
- 次要结局包括严重不良事件与无有创机械通气天数。
核心结论
- 第一步旨在评估脑氧饱和度指导治疗是否增加有创机械通气新生儿的无住院天数。
研究设计与样本
- 研究者发起的多国随机实用优效性 III 期临床试验,本文为第一步方案。
- 计划随机 1,610 例胎龄≥28+0 周、生后<28 天、预计有创机械通气≥24 h 的新生儿,1:1 分组。
- 纳入需在启动有创机械通气后 6 h 内可开始脑氧监测。
- 排除疑似或确诊脑损伤或可能需手术的先天性心脏畸形。
关键数值与推荐
- 主要结局为随机后 90 天无住院天数。
- 次要结局为严重不良事件和无有创机械通气天数,均在随机后 90 天评估。
- 干预组按 SafeBoosC 治疗指南进行脑氧饱和度指导治疗。
临床怎么用
- 对符合条件的有创机械通气新生儿,可在启动通气 6 h 内启动脑氧监测并按指南指导治疗。
局限性
- 第二步目前缺乏资金。
- 临床工作人员未设盲。
- 临床医生使用该设备的经验可能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of invasive mechanical ventilation in newborns has several risks, including ventilator-induced lung injury, ventilation-associated pneumonia, and hyperventilation leading to potential brain injury, prolonged hospitalisations, and increased mortality. The SafeBoosC-IIIv trial aims to assess the benefits and harms of treatment guided by cerebral oximetry monitoring in newborns receiving invasive mechanical ventilation within the first 28 days from birth. The SafeBoosC consortium is a global network of neonatologists from multiple neonatal intensive care units worldwide. METHODS: The SafeBoosC-IIIv trial is an investigator-initiated, multinational, randomised, pragmatic, superiority phase III clinical trial. The trial will be conducted in two steps. This is a protocol for step one. The objective of step one is to assess if treatment guided by cerebral oximetry monitoring according to the SafeBoosC treatment guideline compared with usual care in newborns receiving invasive mechanical ventilation increases the number of hospital-free days. The participants will be newborns with a gestational age more than or equal to 28 + 0 weeks, postnatal age less than 28 days, expected to receive invasive mechanical ventilation (intubation) for at least 24 h, and a cerebral oximeter available so monitoring can be started within 6 h after initiation of invasive mechanical ventilation. Exclusion criteria will be suspicion of or confirmed brain injury or congenital heart malformation likely to require surgery. A total of 1,610 participants will be randomised 1:1 to treatment guided by cerebral oximetry monitoring or usual care. The primary outcome will be hospital-free days, and the secondary outcomes will be serious adverse events and invasive mechanical ventilation-free days. All outcomes will be assessed at 90 days after randomisation. DISCUSSION: The SafeBoosC-IIIv trial has several strengths, including detailed predefined methodology, a high degree of external validity due to centres in several countries, and the trial will be built upon the already established SafeBoosC consortium and the experience from the previous SafeBoosC-II and SafeBoosC-III trials. The SafeBoosC-IIIv trial has limitations, including current lack of funding for step two, lack of blinding of the clinical staff, and the clinicians may have limited experience in using the device. TRIAL REGISTRATION: ClinicalTrials.gov: NCT05907317, registered 8 June 2023, https://clinicaltrials.gov/study/NCT05907317?cond=NCT05907317&rank=1.
引用
- Kamp CB, Petersen JJ, Hansen ML, et al. Treatment guided by cerebral oximetry in newborns receiving invasive mechanical ventilation: study protocol for step one of the SafeBoosC-IIIv randomised clinical trial. Trials. 2026. PMID: 41845443. doi:10.1186/s13063-026-09631-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。